Sunday 18 October 2026
Export RNA’s income statement to Excel — free account
Atrium Therapeutics, Inc.
RNA
Atrium Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.8 million, up 72.1% from fiscal 2024. Revenue growth for three consecutive years.
7.67
0.15
−1.92%
Follow RNA
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+1 more quarter Free account |
0.00 | — | 0.00 | 0.00 |
P/S ratio |
0.00 | — | 0.00 | 8.20 | |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | |
P/Operating CF |
(21.19) | — | (7.34) | (58.60) | |
P/B ratio |
0.00 | — | 0.98 | 1.07 | |
Price to Tangible BV |
0.00 | — | 0.98 | 1.07 | |
EV/Sales |
0.00 | — | 0.00 | (1.22) | |
EV/EBITDA |
0.00 | — | 0.00 | 0.57 | |
EV/Operating CF |
0.00 | — | 0.00 | 0.59 | |
EV/FCF |
0.00 | — | 0.00 | 0.59 | |
Quick Ratio |
— | 0.00 | 12.91 | 8.39 | |
Current Ratio |
— | 0.07 | 13.04 | 8.73 | |
Net Debt/EBITDA |
0.00 | — | 15.64 | 11.73 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | — | — | 0.20 | |
Operating CF/Net income |
0.92 | — | 1.87 | 0.19 | |
Capex/Depreciation |
(3.37) | — | (13.89) | (0.39) | |
Research and Development Expense of Revenue |
345.54% | — | 84.83% | 510.75% | |
Selling, General and Administrative Expense of Revenue |
88.85% | — | 103.17% | 342.18% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
44.19% | — | 62.20% | 29.73% | |
Graham Net Nets |
(0.27) | — | 0.99 | 0.91 | |
Graham Number |
0.00 | — | 0.00 | 0.00 | |
Earnings Yield |
(24.82%) | — | (24.82%) | (24.82%) | |
Free Cash Flow Yield |
0.00% | — | 0.00% | (25.24%) | |
Revenue per Share |
0.22 | — | 1.15 | 0.18 | |
Operating CF per Share |
(0.70) | — | (1.82) | (0.23) | |
Capex per Share |
(0.02) | — | (0.12) | 0.00 | |
Free Cash Flow per Share |
(0.71) | — | (1.94) | (0.23) | |
Cash per Share |
0.00 | — | 15.66 | 15.45 | |
Shareholders Equity per Share |
0.00 | 0.00 | 13.69 | 12.54 | |
Interest Debt per Share |
0.00 | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 13.69 | 12.54 | |
Free Cash Flow |
(12.17) | — | (33.24) | (3.96) | |
Working Capital |
— | (38.96) | 263.66 | 243.54 | |
Capital Expenditures |
(0.27) | — | (2.10) | (0.04) | |
Net Current Asset Value |
0.00 | (68.22) | 227.31 | 209.12 | |
EV/EBIT |
0.00 | — | 0.00 | 0.57 | |
Capex to Sales |
0.07 | — | 0.11 | 0.01 | |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Assets |
— | — | — | 140.26 |
Columns are period end dates